BioStock

Prenumeration

Biosergen AB: BioStock: Biosergen on dosing the first patient with life-threatening fungal disease

2024-07-18 11:59:36

The first patient has been dosed in Biosergen's clinical phase Ib trial with BSG005, intended as rescue therapy for invasive fungal infection to increase survival rates for these critically ill patients. Topline results are anticipated by year-end or early 2025. BioStock reached out to CEO Tine Kold Olesen to learn more about the latest achievement.

Read the interview at biostock.se:
https://www.biostock.se/en/2024/07/biosergen-on-dosing-the-first-patient-with-life-threatening-fungal-disease/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden